What question did this study set out to answer?

The study aims to identify prognostic factors in leiomyosarcoma and evaluate the efficacy of various treatment strategies.

March 12, 2026ESMO rare cancers.Open Access

138P Clinicopathological features, treatment outcomes, and prognostic factors in leiomyosarcoma: A 24-year experience from a single center

View Full Paper

Ask AI

Bookmark

The study aims to identify prognostic factors in leiomyosarcoma and evaluate the efficacy of various treatment strategies.
Retrospective analysis of clinical, pathological, treatment, and survival data
Analyzed patients treated at Zhejiang Cancer Hospital from 2000 to 2024
Assessed progression-free survival and overall survival rates
5-year PFS of 18.8% and OS of 61.6%, with median PFS of 17.5 months and median OS of 94.3 months
Advanced age, grade 3 tumors, and stage IV disease linked to poor prognosis
For stage I uterine LMS, treatments like oophorectomy and chemotherapy did not significantly improve survival
For metastatic LMS, gemcitabine plus docetaxel showed better efficacy than anthracycline therapy.

No takes yet. Share an insight, caveat, or question.

This retrospective study analyzes treatment outcomes in leiomyosarcoma, highlighting prognostic factors and treatment implications.

Qi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark